Beta Bionics, Inc. (BBNX) stock
BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/306% above fair value
$16.42−0.09 (-0.55%)
Close on Nov 13, 2026Market cap $892.71MP/E –Yield –
Beta Bionics gross margin
Gross margin is gross profit as a percentage of revenue.
Beta Bionics's gross margin for the twelve months ending Sep 30, 2026 was 58.6%. For fiscal 2025 it was 55.4%, against 55.1% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 55.4% | +0.3 |
| FY2024 | Dec 31, 2024 | 55.1% | +2.5 |
| FY2023 | Dec 31, 2023 | 52.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 57.3% | +1.8 |
| Q2 FY2026 | Jun 30, 2026 | 59.0% | +5.2 |
| Q1 FY2026 | Mar 31, 2026 | 59.5% | +8.6 |
| Q4 FY2025 | Dec 31, 2025 | 59.0% | +1.8 |
| Q3 FY2025 | Sep 30, 2025 | 55.5% | +2.1 |
| Q2 FY2025 | Jun 30, 2025 | 53.8% | +0.1 |
| Q1 FY2025 | Mar 31, 2025 | 50.9% | −4.8 |
| Q4 FY2024 | Dec 31, 2024 | 57.2% | – |
| Q3 FY2024 | Sep 30, 2024 | 53.4% | – |
| Q2 FY2024 | Jun 30, 2024 | 53.7% | – |
| Q1 FY2024 | Mar 31, 2024 | 55.7% | – |
See a number that looks wrong?